Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
Primary objective is to evaluate the neuroprotective effect of T-817MA on Tau protein phosphorylated at threonine 181 (p-tau 181) in cerebrospinal fluid (CSF) compared with placebo in patients with a diagnosis of MCI due to AD or mild AD.
Secondary objectives are:
To evaluate in patients on T-817MA and placebo:
To evaluate the safety of T-817MA by clinical laboratory tests and adverse events (AEs).
To evaluate the pharmacokinetics of T-817MA
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
Key Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
221 participants in 2 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal